IL2 and neoplasm: As shown in Fig. 5 and Tables 2 and 3, CCR4‐IL2 bispecific IT prolonged the tumor‐bearing animal survival significantly longer than IL2‐CCR4 bispecific IT (median survival days of 69 vs 57).